Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898985 | 1.00 | CA2 (0.51) | CA2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL27101546 | 1.00 | CA2 (0.51) | CA2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL29400332 | 1.00 | CA2 (0.51) | CA2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL3366913 | 0.92 | FPR2 (0.53) | MDM4TP53PTPN1SLC17A5MDM2 | |
| SCHEMBL119512 | 0.92 | FPR2 (0.53) | MDM4TP53PTPN1SLC17A5MDM2 | |
| SCHEMBL119309 | 0.92 | FPR2 (0.53) | MDM4TP53PTPN1SLC17A5MDM2 | |
| SCHEMBL29402299 | 0.92 | FPR2 (0.53) | MDM4TP53PTPN1SLC17A5MDM2 | |
| SCHEMBL29907959 | 0.92 | FPR2 (0.53) | MDM4TP53PTPN1SLC17A5MDM2 | |
| SCHEMBL9732381 | 0.91 | PTPN1 (0.54) | MDM4TP53PTPN1SLC17A5MDM2 | |
| SCHEMBL29843110 | 0.91 | PTPN1 (0.54) | MDM4TP53PTPN1SLC17A5MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478311-B1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | UNIV CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250362310-A1 | STRUCTURE-BASED PROBE FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-10-23 | — | — | US | disclosed |
| EP-4618968-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | Technion Research & Development Foundation Limited (IL) | 2025-09-24 | — | — | EP | disclosed |
| EP-3596102-B1 | STRUCTURE-BASED PEPTIDE INHIBITORS THAT TARGET THE TAU VQIINK FIBRILLIZATION SEGMENT | UNIV CALIFORNIA (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-11390646-B2 | Structure-based peptide inhibitors of α-synuclein aggregation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-8048906-B2 | Optically pure and enriched isomers of chelating ligands and contrast agents | CATALYST MEDICAL (US) | 2011-11-01 | — | — | US | disclosed |
| EP-1641495-A4 | OPTICALLY PURE AND ENRICHED ISOMERS OF CHELATING LIGANDS AND CONTRAST AGENTS | EPIX PHARM INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20070244316-A1 | Optically pure and enriched isomers of chelating ligands and contrast agents | EPIX PHARMACEUTICALS, INC. A DELAWARE CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-20060155120-A1 | Optically pure and enriched isomers of chelating ligands and contrast agents | CATALYST MEDICAL | 2006-07-13 | — | — | US | disclosed |
| CN-1795015-A | optically pure and optically enriched isomers of chelating ligands and contrast agents | EPIX PHARM INC (US) | 2006-06-28 | — | — | CN | disclosed |
| EP-1641495-A2 | OPTICALLY PURE AND ENRICHED ISOMERS OF CHELATING LIGANDS AND CONTRAST AGENTS | EPIX Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005001415-A2 | OPTICALLY PURE AND ENRICHED ISOMERS OF CHELATING LIGANDS AND CONTRAST AGENTS | EPIX PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390646-B2 | Structure-based peptide inhibitors of α-synuclein aggregation | SNCA, PARK7, IAPP | CA2 4743/4885MDM4 970/4885TP53 827/4885 |
| US-20070244316-A1 | Optically pure and enriched isomers of chelating ligands and contrast agents | AOC1, TFRC, UACA | CA2 982/4885MDM4 2073/4885TP53 2927/4885 |
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | PSMC1, PSME3, PSMA6 | CA2 4325/4885MDM4 1440/4885TP53 595/4885 |
| US-20060155120-A1 | Optically pure and enriched isomers of chelating ligands and contrast agents | AOC1, TFRC, UACA | CA2 982/4885MDM4 2073/4885TP53 2927/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CA2 3665/4885MDM4 3040/4885TP53 421/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CA2 3067/4885MDM4 2686/4885TP53 428/4885 |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | TTR, APP, SERPINA3 | CA2 4011/4885MDM4 2595/4885TP53 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.